Report library

Simponi

Simponi (golimumab; Johnson & Johnson/Merck & Co/Mitsubishi Tanabe) is a second-generation TNF inhibitor following Johnson & Johnson’s Remicade (infliximab).

May 18, 2018

Tildrakizumab

Tildrakizumab is a monoclonal antibody that targets IL-23. IL-23 is part of the IL-12 cytokine family,
the master regulator of the TH1 pathway which drives major chronic inflammatory diseases

August 10, 2016

Disease Analysis: Diabetic Nephropathy

Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether.

March 11, 2022

Specialty Endoscopic Surgery Devices Market

The global market for specialty endoscopic surgery products totaled approximately $5.8bn in 2016, with the US comprising 48.2% of sales (or $2.8bn). Six major product segments are included in the specialty endoscopic surgery products market: endoscopes and equipment; suction/irrigation and fluid management systems, arthroscopic hand instruments, ENT/neurologic hand instruments, thoracoscopic hand instruments, and trocars.

August 23, 2017

Zoladex

Zoladex (goserelin; AstraZeneca/TerSera Therapeutics) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”

January 18, 2018

U.S. Markets for Respiratory Care Products, June 2016

The annual U.S. economic burden of respiratory disease is more than $106 billion. Appropriate therapy can reduce direct healthcare costs as well as indirect costs such as lost worker productivity. The combined U.S. market for respiratory products totalled more than $4.4 billion in 2015.

June 20, 2016

Taltz

Taltz (ixekizumab; Eli Lilly/Torii Pharmaceutical) is a humanized, immunoglobulin G subclass 4 monoclonal antibody that neutralizes interleukin-17.

May 18, 2018

Disease Analysis: Hepatocellular Carcinoma (HCC)

Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.

May 19, 2022

Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

April 1, 2020

Pharma’s Patient Centricity

$2,995.00

Patient centricity is the buzzword of this decade, and necessarily so: it either underpins, or is an inevitable result of, all the forces shaping today’s rapidly evolving healthcare landscape.

October 17, 2016

Global Diabetes Management Devices Market

The global market for diabetes management devices—valued at more than $9bn in 2015—is a substantial, highly competitive market driven by highly sophisticated, evolving technology, particularly in the insulin pump/artificial pancreas and CGM area.

March 30, 2017

Zevalin

Zevalin (ibritumomab tiuxetan; Acrotech Biopharma/Mundipharma) is an intravenous radioactive agent consisting of the murine monoclonal antibody (MAb) ibritumomab, which is covalently linked to the chelator tiuxetan.

January 30, 2019

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #1

This interview covers hepatocellular carcinoma treatment trends in the US. We discuss current treatment options including the recently approved Keytruda and Lenvima. Also disused are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.

February 6, 2019

F/TAF

F/TAF (emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a fixed-dose combination of two of Gilead’s nucleoside reverse transcriptase inhibitors, Emtriva (emtricitabine) and GS-7340 (TAF).

December 11, 2015

NeoRecormon

NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD).

January 11, 2018

Kogenate

Kogenate (recombinant factor VIII [rfVIII]; Bayer/CSL Behring) – is a recombinant antihemophilic factor indicated for the control and prevention of bleeding episodes, perioperative management, and for routine prophylaxis in children and adults.

May 4, 2018

France Generics and Biosimilars

$2,995.00

Traditionally considered an immature generics market, France has seen the introduction of measures aimed at increasing generics use in order to cut healthcare costs.

November 3, 2016

Elafibranor

Elafibranor (Genfit) is an oral peroxisome proliferator-activated receptor (PPAR) alpha-delta dual agonist. The medication activates PPAR-alpha and PPAR-delta, which control gene expression. Stimulating these receptors increases insulin sensitivity and fatty acid oxidation, which results in a reduction of fat buildup in the liver and leads to a decrease in fibrosis and inflammation.

July 22, 2019

Ebola KOL Interview #3

Ebola KOL Interview #3

December 2, 2014

Copiktra

Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme.

January 31, 2019

Iomab-B

Iomab-B is a radioimmunotherapy comprised of the monoclonal antibody BC8 coupled with the radioisotope Iodine-131.

July 6, 2017

Alunbrig

Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

September 8, 2018

Neurointervention: Mechanical Thrombectomy Devices Market

This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and arteriovenous malformation (AVM) embolization systems.

October 30, 2020

Mircera

Mircera is an ESA administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in CKD

January 11, 2018

Lovenox

Lovenox (enoxaparin; Sanofi/Kaken Pharmaceutical) is a subcutaneous low molecular weight heparin approved for the prophylaxis of deep vein thrombosis (DVT)…

August 2, 2016

Semaglutide (Oral)

Novo Nordisk’s semaglutide is an orally available GLP-1 agonist currently being investigated in Phase
III trials for the treatment of type 2 diabetes. GLP-1 agonists are incretin mimetics, mimicking the
endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.

June 23, 2016

Adynovate

Adynovate is a long-acting PEGylated recombinant factor VIII (rfVIII) therapy developed by Baxalta and Nektar Therapeutics as a follow-on to Advate (rfVIII; Shire).

May 4, 2018

Women’s Health: Trends and Opportunities in the U.S. Osteoporosis Management Market

$3,750.00

This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products.

September 2, 2013

2014 October Dermatology Survey

We performed a 5-question survey of 21 dermatologists to gauge usage of drugs and devices for the treatment of common dermatological conditions and for aesthetic procedures.

October 30, 2014